CEOInterviews.AI
Start App
Get an email when Tom Hale gives a new interview
One email per new interview. Unsubscribe in one click.
Tom Hale
Chief Executive Officer, Oura

Oura CEO on Future of Health, Brex CEO on Fintech’s Growth, AI for Science Discovery | Oct 14, 2025

📅 Oct 14, 2025 The Information 35 MIN 553 VIEWS 79 SEGMENTS · 5 SPEAKERS
Oura CEO Tom Hale talks with TITV Host Akash Pasricha about raising $900M at an $11B valuation and the company's AI-driven plans for the future of health tech. We also talk with Brex CEO Pedro Franceschi about the company's "unconstrained ambition" and how they're competing with incumbents. The Information's Stephanie Palazzolo explains the rise of "NeoClouds" and the race to rent out NVIDIA chips. Lastly, we get into AI-powered material science with Radical AI CEO Joseph Krause. Articles discussed on this episode: https://www.theinformation.com/articl... TITV airs on YouTube, X and Lin...

Questions asked in this interview

9
  1. 1:54And my question is, why do you need to raise the money if you're profitable?
  2. 3:30What are you using them for?
  3. 4:46And so how do you create an intelligence that supports the vast diversity of both health conditions, people, ethnicities, these races around the planet?
  4. 5:24And so, are you concerned at all that this is going to lower your profitability margin as you look to build out AI at all, or how do you think about that?
  5. 6:55I mean, how do you think about building this as a standalone company versus something that, you know, honestly could fit very nicely into a bigger tech company?
  6. 7:42And you think you can do it alone?
  7. 8:55How much money do you make on selling the device itself?
  8. 9:44How much is the contribution margin on the devices?
  9. 10:23Can we expect Oura to seek FDA approval for any of its products in the coming year or two?
Akash Pasricha 0:13 ↗
Welcome everyone to The Information TITV. My name is Akash Pasricha. It is Tuesday, October 14th. We have got another full tour of the tech sector today for you folks. We are talking about health tech with the CEO of Oura. We are also talking fintech with the CEO of Brex. We're then going to talk about the race to rent out Nvidia chips. And finally, we have a great discussion planned for you about how AI can actually have an impact on the physical world. But before we get going, I want to highlight for you a big story that we published last night. The Information is first to report that OpenAI is working with Arm, the chip company owned in large part by SoftBank, to develop CPUs. A reminder that CPUs are different from GPUs, the AI chips that have taken the world by storm. But the key thing here is that all AI chips need CPUs to work. And so that is why this story is important. The news came on the heels of OpenAI's announcement that it is working with Broadcom to jointly develop their own chip. And so this is a big story. It moved Arm shares after hours last night, I should say. They continue to move this morning. We will link it in the show notes. And with that, let's get to our first guest. Oura has made big news today, announcing it has raised $900 million at an $11 billion valuation. The investment was led by Fidelity Management and Research Company with participation from Dexcom. The company is on track to pass $1 billion in annual sales this year. And I want to bring on Tom Hale, the CEO of the company, to share more about where he plans to take Oura in this next phase of growth. Tom, welcome to TITV. It's great to see you again.
Tom Hale 1:51 ↗
Great to see you, Akash. Thanks for having me.
Akash Pasricha 1:54 ↗
So, a big day for Oura. The place I want to start with the company is: last time you were on the show a couple months ago with editor-in-chief Jessica Lessin, you mentioned to her that the company's profitable, and yet you've still raised all this money. And my question is, why do you need to raise the money if you're profitable?
Tom Hale 2:10 ↗
Well, good news. Everyone knows that AI is incredibly expensive, and I think AI and the future of healthcare are intertwined. So I think we want to make sure that we have that ability to invest in AI, particularly as we think about acquiring talent and making investments and maybe ultimately developing our own models. So this is certainly the first thing that we want to invest in. The second thing, of course, is that we're still at the very beginning of this business. Oura has been on a tear. We've been doubling the business year over year. We're about to reach a billion dollars in sales, and the reality is we're just getting started because we're barely just in the US today. So we've got a lot of headroom and expansion around the globe, and I think that's going to take us a fair amount of investment to make sure that we can cover the planet. And the last piece, of course, is healthcare. Our vision always has been to be a wearable that is across the entire surface of holistic health, and healthcare is in transformation right now. We don't have enough doctors. We don't have enough preventative medicine. You know, the prediction that we do, some of the practices that are grounded in science are still, you know, they're dated data. We have up-to-date current data on the people who are wearing the ring. We want to take that data and make it present in health. And I think that's a very different kind of company than what we've been today. And so we need to invest in the talent, in the people, in the process, in the systems, in the science to really make a healthcare journey for Oura take its next stride.
Akash Pasricha 3:30 ↗
Whose AI models are you using right now? What are you using them for?
Tom Hale 3:34 ↗
We use almost every model that's available. And I think we have a range of things that we do. It starts, of course, with the predictions that the system makes, using algorithms that are basically there to tell you what are the values that we're deriving from the signals that we're taking off of your body. And we've been doing that for 10 years. We're probably maybe the best in the world at these kinds of algorithms for signal processing.
Akash Pasricha 3:55 ↗
And so we're talking a combination of open source models, closed source models. I mean, you know, the big models like OpenAI.
Tom Hale 4:02 ↗
Well, so for those models, those are almost entirely developed by us, although we're using all the tools. The second place is this kind of idea of what you might think of as the doctor in your pocket, right? You've already got a supercomputer, you've got a wearable device. There's some intelligence that's looking over that data, knows lots of things about you that you've shared with it — your context, your health history, your tags, your biometrics — and making sense of that. That is actually really another form of this AI, and that's largely models we develop. Then there's interpretation and presentation of insights. So basically you might want to interrogate your data and say, 'What's going on?' and an LLM-type application will respond to you and say, 'Well, this is what's going on,' or you might ask for advice, and those LLMs are, I think, you know, what you would expect to be the classic LLMs and the open source and closed source models that are available.
Akash Pasricha 4:46 ↗
Now, so across all three of those surfaces, you've got a substrate of AI. Now ultimately where I think this all goes is you think about the quality of the data that something like the Oura ring has — meaning it's consistent, it's accurate, it's continuous, it's measured overnight — feeding, call it, a large physiology model with that data is going to be able to create an AI that is effectively targeted and oriented around you, because your health and my health are not the same. And so how do you create an intelligence that supports the vast diversity of both health conditions, people, ethnicities, these races around the planet? I think that's the challenge that we want to invest behind.
I do want to ask you though about the profitability of building out these AI tools, because as you mentioned, the company's profitable now, but we've seen with a lot of these application layer companies, certainly those companies who are looking to build their own models or utilizing models that exist — I mean, it's expensive right now. There's no two ways about it. And so, are you concerned at all that this is going to lower your profitability margin as you look to build out AI at all, or how do you think about that?
Tom Hale 5:49 ↗
Well, I have a really interesting kind of thesis on this, and I think part of it goes to privacy. People want to have, you know, very strict controls over their health data, and I think that's something that we take as a first principle. And making sure that we don't share your data is like something that Oura, you know, believes in from our foundation. Now, the key is how do you do that in a world where you have AI interpreting or even communicating to you via an LLM about your health? Our vision for this is to put that AI at the edge, meaning that it is on the device that's in front of you. And to the degree that we can put as much of that processing, as much of that AI on a device that's close to you and under your control and is encrypted and maybe locked by your biometrics, that's the vision that we see. Now, the side effect of that is that if you do that, you're also taking advantage of the latent processing power of all these devices, which are underutilized in terms of their computing capability and are accelerating in terms of their power. So part of our vision is to have AI at the edge that is private but also ultimately lower cost. And so that's how we think about that cost problem that you highlight.
Akash Pasricha 6:55 ↗
And I hear you, and it's a tough challenge. You know, it's something that a lot of these wearables companies are thinking about. The other question I wanted to ask is, and you were asked this morning about your plans, whether or not you IPO or not. I mean, how do you think about building this as a standalone company versus something that, you know, honestly could fit very nicely into a bigger tech company? And as you talk about edge computing, you know, the ability to put LLMs on the devices themselves, this is something that, you know, we've heard companies like Apple is even considering.
Tom Hale 7:27 ↗
I think this is the way it's going to go. I think absolutely, and particularly for these kinds of applications. I think actually it's going to be really mandatory to have that privacy at the edge. So I think that is viable. I think that's the path that we're on, and I think that's...
Akash Pasricha 7:42 ↗
And you think you can do it alone?
Tom Hale 7:45 ↗
I don't think anybody in tech does anything alone. Apple is really clear about that. But if you're asking really about us as a standalone company, you know, I mean, we've raised money, and we've raised money at a pretty good valuation based on the back of our financials. Our financials support that valuation. This is not an outrageous valuation. This is not some projected value. This is based on the dollars that we delivered last year and the dollars that we're going to deliver next. So that's relatively comfortable. However, there's a call option here, and that call option is on that future of AI and healthcare, which I think is being transformed. It's happening faster than maybe anyone predicted. And I think that it seems inevitable. And so there's a call option on that, which I think is actually honestly enough to support a company of our size increasing to, you know, from a $10 billion valuation to a 20, a 30, or 40, $50 billion valuation, because the future of healthcare and the way health is managed and delivered, where people are the agents of their own health journey — they are in charge of their own health journey — that change is a transformation that I think is a generational transformation. So I don't think of us as like, 'Oh well, we're a little wearable company.' I think of us as like a platform, an operating system for your health. Think about the value that that could create in the market.
Akash Pasricha 8:55 ↗
Wow. Two more quick questions for you. I wanted to ask about the devices themselves. You introduced some new designs too today. You know, the price point is still around a couple hundred bucks, right? I see the new designs there. How much money do you make on selling the device itself?
Tom Hale 9:14 ↗
So what's amazing is that we make both a contribution margin when we sell our products. So on day one we're profitable on a unit economics basis. That's really powerful, and the reason why it's powerful is because Oura also has a membership model, and that membership model is sort of an ongoing revenue stream. So when we sell a ring, we're making back the cost of acquisition and the cost of manufacturing and a little bit of profit, and then that is a ticket to a subscription business. Right. So our...
Akash Pasricha 9:41 ↗
How much is that contribution?
Tom Hale 9:43 ↗
What do you mean?
Akash Pasricha 9:44 ↗
How much is the contribution margin on the devices?
Tom Hale 9:46 ↗
Oh, it's quite high. I mean, you know, the sort of hardware margins, right? Hardware margins, if they're doing great, are 40%. We're north...
Akash Pasricha 9:53 ↗
Okay.
Tom Hale 9:53 ↗
North of 40%.
Akash Pasricha 9:54 ↗
Okay. Okay.
Tom Hale 9:55 ↗
And by the way, like this is a function of being a really good scaled hardware company delivering that. But then that is a zero CAC ticket to a subscription business. And that elevates our margins even higher. So when you look at Oura's financials, we don't look like a hardware company. We look much more like a software company with a hardware component. I think that's a key, again going back to the valuation of a standalone company, that's one of the keys that allows Oura to be like, you know, at the top of the pile when it comes to valuation.
Akash Pasricha 10:23 ↗
Right. And I should remind people, I mean, you know, this is the second year in a row you're raising money. I don't know if you may have raised money three years in a row, I don't know, but I know you raised another big round last year as well. The last thing I want to ask you before you go is, I know you have a number of partnerships with other companies that have devices that are FDA approved, and we've seen companies like Eight Sleep, for example, coming out and declaring we are going to seek FDA approval for our line of products in the future. Can we expect Oura to seek FDA approval for any of its products in the coming year or two?
Tom Hale 10:53 ↗
Yes, we already have a Class One medical device in our fertile window. Basically, that's the software feature that predicts when a woman is ovulating. So if you're a couple who are trying to conceive, that feature is one that we've worked through the FDA on, and we have others in the pipeline. I think that's part and parcel of kind of our investment towards becoming more and more like a healthcare company. Having FDA approvals is both, you know, important for safety and effectiveness, but it's also a mark of seriousness and confidence that the technology is accurate and that it's, you know, validated by science and that it can be used by clinicians. It's stunning to me the number of people who use Oura as part of their health regime. 10%, 11% of our customers are clinicians of one form or another. So already in the healthcare space, being used in a variety of ways, and we expect to actually extend that further as we work deeper and deeper with the FDA.
Akash Pasricha 11:45 ↗
Great, Tom. Well, thank you so much for coming on the show again. It's always a great conversation. Congrats on the new funding round, and excited to see the new designs as well that are being released today. That is Tom Hale, the CEO of Oura, here on TITV.
Okay. Earlier this month, the CEO of Brex wrote to his employees, boldly declaring that the turnaround is over and the company will now return to unconstrained ambition. I want to bring on Pedro Franceschi, the CEO who wrote that memo, to tell us about how he's shifting his thinking to this new phase of growth for Brex. Pedro, welcome to the show. It's great to have you.
Pedro Franceschi 12:21 ↗
Thanks for having me. Excited to be here.
Akash Pasricha 12:23 ↗
So let's talk about the turnaround being over and this period of unconstrained ambition. I kind of want to segment the discussion into two halves. One is the turnaround, one is the unconstrained ambition. Tell us about what exactly the turnaround is that you're referring to.
Pedro Franceschi 12:38 ↗
Yeah. So maybe let me just start with where we are today. So if you just look at the business over the past, you know, 20 months, we rebuilt entirely how we operate as a company. So when you think about, you know, the way we build products, the way we build our go-to-market, the way we operate, the leadership team, and just the sort of talent density on leadership levels in the company, they are very different from where they were 20 months ago. And I wrote a few memos about this on, you know, having leaders that operate at all levels, changing the way we build a product, and, you know, me as a founder and CEO being much more involved in the product roadmap and the quality of what we ship. And as a result, you know, in August, Brex grew, you know, just shy of 50% year on year and was operating cash flow positive for the first time since its inception. So it's a very different reality from where we were 20 months ago, and, you know, we're very proud of that.
Akash Pasricha 13:31 ↗
And I'm curious that you use the word unconstrained ambition, because one of the things that you talked about is the company has been operating cash flow positive for the first time in its history, and my read on it was, okay, we are returning to focusing on growth now, and growth at all costs sometimes can yield, you know, dicey results, you know, as we've seen with many different companies in Silicon Valley. And so my question for you is, how do you plan to spark this new phase of growth, I guess, while growing profitably? And you know that is the constraint that comes with this ambition, right?
Pedro Franceschi 14:05 ↗
Absolutely. So when we say unconstrained ambition, really what we mean by that is if we just look at the market that we're in today, and I think folks don't necessarily appreciate that, there's $2 trillion of corporate cards spent in the US, and Brex today is like, you know, a little bit over 1% of that. And, you know, if you look at all the new players combined, right, we're maybe two, two and a half percent of the market. So this is a market that's very deeply dominated by incumbents. So you have banks that have been around for decades serving customers in a very poor way, with no software, with no way of actually improving the way they run their business. And when we look at the way customers run their operation with Brex, and you see, you know, companies like Arm, Cursor, Intel, Anthropic, Palantir here, right, all sort of materially changing how their business operates because they partner with Brex — that is really what we're talking about. How do we bring this spirit and this product that we have working so well for this tiny sliver of the market, this 1% of the market, into the, you know, this 98% that's still dominated by incumbents? And that's really what we mean by unconstrained ambition.
Akash Pasricha 15:09 ↗
So how do you do it? How do you do it?
Pedro Franceschi 15:12 ↗
It's just continuing to execute the same level of rigor, raising the bar every day. And just really when you look at the market and you just realize that most people actually have no idea what Brex is or that there's even a better way to think about how you manage your finances as a company, and that's really a very big part of the story. And especially now if you see what's happening with AI, you know, we think there's this bigger opportunity to not just build the financial services, which is what we did early on, and the software, but, you know, effectively all the infrastructure that you build to help these companies replace all the labor that you have traditionally doing work that can now be automated. And we're very excited about the opportunity.
Akash Pasricha 15:51 ↗
And what do you see as the next phase of fintech broadly speaking? Because fintech, it's had a period where we had the zero era, we sort of had the reckoning era, and now people are sort of trying to figure out, okay, what does the next few years look like in your mind? Let's make some predictions here. What are we going to see?
Pedro Franceschi 16:09 ↗
Yeah. So I have a saying that internally, and I guess externally as well, that fintech in the US hasn't really happened yet. So when you look into the percentage of the market that is using a modern solution like Brex, it's so tiny still. So a lot of the work is just getting customers there. It's just literally going after every single business in America using a modern solution and explaining to them, hey, you shouldn't be using American Express, you shouldn't be using your bank card anymore, you shouldn't be using your traditional bill-based solution, and here are the benefits of bringing this all under Brex and how it helps your business move faster, spend smarter, right, and all the benefits that we see customers as they deploy a solution like Brex in their team. So I think that's one, which is, you know, fintech hasn't really happened when you just look at sort of a very mainstream use case. The second one is when you look into what we built, right, and, you know, we made a few decisions that I think were pretty different than other fintechs. You know, everything that you have on the financial services side was built in-house. So all the card payment rails, you know, capital markets, underwriting, credit, we built the entire sort of bank stack in-house. Then we built this partner ecosystem that surrounds our customers, especially larger ones. Every single solution they need, they have deep integration, and we did it slowly, right? So when you look into sort of the breadth and the depth that you have to have to serve these very sophisticated use cases, right? I think that's something that I think will be more of a trend than having that done in fintech as well.
Akash Pasricha 17:34 ↗
I do want to ask you, Ramp raised a ton of money. You guys must be raising too, right?

38 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Hale, T. (2025, October 14). Oura CEO on Future of Health, Brex CEO on Fintech’s Growth, AI for Science Discovery | Oct 14, 2025 [Interview transcript]. The Information. CEOInterviews.AI. https://ceointerviews.ai/interview/3248704/

MLA

Tom Hale. "Oura CEO on Future of Health, Brex CEO on Fintech’s Growth, AI for Science Discovery | Oct 14, 2025." The Information, 14 Oct. 2025. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3248704/.

BibTeX
@misc{hale2025_3248704,
  author       = {Tom Hale},
  title        = {Oura CEO on Future of Health, Brex CEO on Fintech’s Growth, AI for Science Discovery | Oct 14, 2025},
  howpublished = {Interview transcript, The Information. CEOInterviews.AI},
  year         = {2025},
  month        = {oct},
  url          = {https://ceointerviews.ai/interview/3248704/},
  note         = {Speaker-attributed transcript with timestamps}
}